长江生命科技(00775)发盈警 预计中期取得股东应占亏损约1.5亿港元 同比盈转亏

Core Viewpoint - Changjiang Life Science Technology (00775) expects to report a shareholder loss of approximately HKD 150 million for the six months ending June 30, 2025, compared to a profit of HKD 1 million in the same period of 2024, primarily due to the company's decision to increase R&D investment [1] Group 1 - The company anticipates a significant shift from profit to loss in its financial performance [1] - The expected loss is attributed to increased investments in research and development [1] - Overall, the company's operations have remained stable during the reporting period and up to the date of the announcement [1]